Benmelstobart in Combination With Anlotinib and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Epithelial OvariaN, Fallopian Tube, or Primary Peritoneal Cancer

ConditionsOvarian Cancer Fallopian Tube Cancers Primary Peritoneal Cancer

Trial statusNot yet recruiting

Trial phasePhase 2

Trial typeInterventional

Biological sexFemale

Age18+

SponsorSecond Affiliated Hospital, School of Medicine, Zhejiang University

About this trial

Efficacy and safety of Benmelstobart combined with Anlotinib and oral metronomic Cyclophosphamide in the treatment of recurrent epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer (BACON study) in China

Eligibility criteria

Qualifiers

1.The age on the day of signing the informed consent form is 18 years or older. 2.Eastern Cooperative Oncology Group performance status of 0-1, with the ability to tolerate chemotherapy.

Disqualifiers

None

Trial design

Treatments tested in this trial

Benmelstobart in combination with Anlotinib and oral metronomic Cyclophosphamide

Treatment groups

40 Participants

are divided into 1 treatment group

Locations

This trial has no locations

Sponsors and collaborators

Second Affiliated Hospital, School of Medicine, Zhejiang University

Lead sponsor

Source ClinicalTrials.gov